Switch to:
Allergan PLC (NYSE:AGN)
Research and Development
$2,511 Mil (TTM As of Sep. 2015)

This is the expense the company spent on research and development. Allergan PLC's research and development for the three months ended in Sep. 2015 was $1,261 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2015 was $2,511 Mil.


Definition

This is the expense the company spent on research and development.

Allergan PLC Research & Development for the trailing twelve months (TTM) ended in Sep. 2015 was 364.6 (Dec. 2014 ) + 431 (Mar. 2015 ) + 454.9 (Jun. 2015 ) + 1260.5 (Sep. 2015 ) = $2,511 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Allergan PLC Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 1311451701972962954026171,0862,359

Allergan PLC Quarterly Data

Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15
Research & Development 1591901721583923654314551,261431
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK